Table of Content


Chapter 1 Introduction
Study Goals and Objectives
Scope of Report
Methodology
Information Sources
Analyst’s Credentials
Chapter 2 Summary
Chapter 3 Overview
Introduction to Peanut Allergy
Etiology and Pathophysiology
Etiology
Pathophysiology
Diagnosis of Peanut Allergy
History
Skin Prick Test (SPT)
Specific IgE (sIgE)
Component-Resolved Diagnosis (CRD)
Oral Food Challenge
The Basophil Activation Test
Epidemiology
Chapter 4 Unmet Needs
Current Unmet Needs in Managing Peanut Allergies
What We Know
Unmet Needs
Emerging Treatments: Immunotherapies
What We Know
Unmet Needs
Unintentional and Casual Exposures
What We Know
Unmet Needs
Chapter 5 The Economic Impact of Peanut Allergies
Burden of Peanut Allergies
Direct Medical and Indirect Costs
Quality of Life
Current and Future Management of Peanut Allergies: Implications for Managed Care
Economic Analysis of Oral Immunotherapy
Barriers to OIT
Chapter 6 PALFORZIA: Overview and Market Outlook
Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Safety and Efficacy
Adverse Effects
Dosage, Administration and Cost
Risk Evaluation and Mitigation Strategy
Current Status of PALFORZIA
Regulatory
Commercialization
Market Analysis
Incidence of Peanut Allergy
The Role of Parents
The Role of Allergists
The Role of Payers
Large Addressable Market
Sales Launch Curve
Chapter 7 Peanut Allergy Prevention Guidelines
Australia
U.S. and Canada
Addendum Guideline 1
Addendum Guideline 2
Addendum Guideline 3
Chapter 8 Emerging Therapies
Viaskin Peanut: DBV Technologies
Product Description
Clinical and Regulatory Activities
CA002: Camallergy
Product Description
Clinical and Regulatory Activities
PRT100: ProTA Therapeutics
Product Description
Clinical and Regulatory Activities
Dupixent (Dupilumab): Regeneron
Product Description
Clinical and Regulatory Activities
Chapter 9 Regulatory Structure
Regulations in U.S.
New Drug Approval
The FDA Modernization Act of 1997
Fast Track Status
Special Protocol Assessments
New Surveillance and Safety Requirements
Medicare
Regulations in Europe
Pricing and Reimbursement
Regulations in Japan
Chapter 10 Company Profiles
AIMMUNE THERAPEUTICS INC.
ALERE INC.
ALLERGAN PHARMACEUTICALS
ALK-ABELLO A/S
ALLERGOPHARMA
ANI BIOTECH OY
BECKMAN COULTER/DANAHER
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
GLAXOSMITHKLINE
HITACHI CHEMICAL DIAGNOSTICS INC.
JUBILANT HOLLISTERSTIER
LABORATORY CORP. OF AMERICA HOLDINGS
LINCOLN DIAGNOSTICS INC.
QUEST DIAGNOSTICS
SIEMENS HEALTHCARE
SMARTPRACTICE DENMARK
TARO PHARMACEUTICAL INDUSTRIES
TERUMO MEDICAL CORP.



List of Figures


Figure 1 : Pathophysiology of Peanut Allergy
Figure 2 : Claim Lines with Diagnoses of Peanut Allergy and Anaphylactic Reaction to Peanuts, by Age Group, 2007-2016

 

List of Tables


Table 1 : Target System Involvement in the Presentation of Peanut Allergy
Table 2 : Characteristics of Peanut Allergens
Table 3 : Estimated Prevalence of Peanut Allergy Cases in Eight Major Markets, Through 2025
Table 4 : Summary of Unmet Needs in Peanut Allergy
Table 5 : Direct Medical Costs of Childhood Food Allergy
Table 6 : Out-of-Pocket Costs* of Childhood Food Allergy
Table 7 : Summary of Addendum Guidelines for Prevention of Peanut Allergy
Table 8 : Alere’s Product Portfolio
Table 9 : Allergan’s Product Portfolio
Table 10 : ALK-Abell?’s Product Portfolio
Table 11 : Allergopharma’s Product Portfolio
Table 12 : Ani Biotech Oy’s Product Portfolio
Table 13 : Beckman Coulter’s Product Portfolio
Table 14 : Cortez Diagnostics’ Product Portfolio
Table 15 : GlaxoSmithKline’s Product Portfolio
Table 16 : Hitachi Chemical Diagnostics’ Product Portfolio
Table 17 : Jubilant HollisterStier’s Product Portfolio
Table 18 : LabCorp’s Product Portfolio
Table 19 : Lincoln Diagnostics’ Product Portfolio
Table 20 : Quest Diagnostics’ Product Portfolio
Table 21 : Siemens Healthcare’s Product Portfolio
Table 22 : SmartPractice Denmark’s Product Portfolio
Table 23 : Terumo Medical’s Products Portfolio